Skip to content

Baxter International Inc

US · BAX #1293 by market cap Listed 2015
25.39 0.00 0.00%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:33

✦ Quant Ownership Signal how this is computed

Mixed / stable
  • The number of reporting institutions decreased by 1 in the most recent period (2026/Q4).
  • Total institutional ownership (as a % of shares) was little changed.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
103.51% 0.00pp
Institutions
886 -1
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund91.73%
Hedge Fund4.23%
Public Company2.98%
Private Company2.24%
Government Pension Fund1.08%
Sovereign Wealth Fund0.81%
Individual/Insider0.42%
Insurance Company0.17%
Family Office/Trust0.13%

Top holders as of 2026-09-30

BlackRock 12.67% · 65.54M sh
Pzena Investment Management, Inc. 12.07% · 62.43M sh
Dodge & Cox 10.76% · 55.65M sh
Vanguard Capital Management, LLC 7.12% · 36.83M sh
FMR 6.20% · 32.10M sh
Vanguard Portfolio Management, LLC 4.53% · 23.41M sh
State Street Global Advisors 3.99% · 20.62M sh
Strategic Advisers LLC 3.74% · 19.36M sh
Geode Capital Management, LLC 2.69% · 13.93M sh
Greenhaven Associates Inc 2.40% · 12.40M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 24 buys · 16 sells

NameRoleStake
Jose Almeida Former Advisor 0.11%
Jeanne Mason Former Chief Human Resources Officer 0.04%
Heather Knight Former Executive VP, COO and Interim Group President of Medical Products & Therapies 0.03%
Reazur Rasul Former Executive VP & Group President of Healthcare Systems and Technologies 0.02%
Christopher Toth Chief Executive Officer 0.02%
David Rosenbloom Executive Vice President 0.02%
Maria Soriano -- 0.01%
Joel Grade Former Chief Financial Officer 0.01%
David Shafer Independent Chairperson 0.01%
Andrew Hider CEO, Pres., Interim Group Pres. of Medical Products & Therapies and Director 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-30 John Rogers Chief Financial Officer Initial Statement of Beneficial 0 --
2026-09-14 Bernie Heine Interim Chief Accounting Officer & Controller Initial Statement of Beneficial 0 --
2026-09-01 Andrew Hider CEO, Pres., Interim Group Pres. of Medical Products & Therapies and Director Sale to Issuer -54,276 $25.70
2026-09-01 Julie Foster President of Front Line Care Sale to Issuer -2,098 $25.70
2026-08-31 James Teaff President of Care & Connectivity Solutions Sale to Issuer -750 $25.48
2026-06-01 Steven Wallace President of Advanced Surgery & Commercial Excellence Sale to Issuer -153 $18.68
2026-06-01 James Teaff President of Care & Connectivity Solutions Sale to Issuer -321 $18.68
2026-05-31 Anita Zielinski Former Interim CFO, Senior VP, Chief Accounting Officer & Controller Other Acquisition +13,426 --
2026-05-04 Michael McDonnell Independent Director Other Acquisition +12,836 --
2026-05-04 Amy McBride-Wendell Independent Director Other Acquisition +12,836 --
2026-05-04 Patricia Morrison Independent Director Other Acquisition +12,836 --
2026-05-04 Nancy Schlichting Independent Director Other Acquisition +12,836 --
2026-05-04 David Shafer Independent Chairperson Other Acquisition +12,836 --
2026-05-04 Jeffrey Craig Independent Director Other Acquisition +12,836 --
2026-05-04 David Wilkes Independent Director Other Acquisition +12,836 --
2026-05-04 William Ampofo Independent Director Other Acquisition +12,836 --
2026-03-31 Steven Wallace President of Advanced Surgery & Commercial Excellence Initial Statement of Beneficial 0 --
2026-03-31 Julie Foster President of Front Line Care Initial Statement of Beneficial 0 --
2026-03-31 James Teaff President of Care & Connectivity Solutions Initial Statement of Beneficial 0 --
2026-03-05 Joel Grade Former Chief Financial Officer Sale to Issuer -8,153 $17.69

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:33:57 · For reference only, not investment advice and not tailored to your situation.

Baxter International Inc discussion 0 comments

Add a comment